On-co-Inventions将Jared Rushton加入其董事会,标志着战略领导力的转变。 Onco-Innovations adds Jared Rushton to its board, signaling strategic leadership shift.

自2025年10月31日起,On-co-Novationations Limited已任命Jared Rushton为董事会董事。 Onco-Innovations Limited has appointed Jared Rushton to its board of directors, effective October 31, 2025. 生物制药公司没有披露任命的具体理由,但这一举动表明,随着以肿瘤为重点的药物开发管道的推进,领导层发生了战略转变。 The biopharmaceutical company did not disclose specific reasons for the appointment, but the move signals a strategic shift in leadership as it advances its oncology-focused drug development pipeline. Rushton带来了制药和公司治理方面的经验,尽管公告中没有提供关于他背景的进一步详情。 Rushton brings experience in pharmaceuticals and corporate governance, though no further details about his background were provided in the announcement.